Cancer pain management of adenoid cystic carcinoma patient with high dose of controlled-release Oral Morphine Sulfate at outpatient clinic.

1997 ◽  
Vol 9 (4) ◽  
pp. 288-293
Author(s):  
Takamichi Yanagisawa ◽  
Yumiko Takahashi ◽  
Masao Kawanaka ◽  
Masahiro Urade
Keyword(s):  
Pain Management ◽  
Controlled Release ◽  
Cancer Pain ◽  
Adenoid Cystic Carcinoma ◽  
Outpatient Clinic ◽  
Oral Morphine ◽  
Morphine Sulfate ◽  
High Dose ◽  
Cancer Pain Management ◽  
Adenoid Cystic

scholarly journals Noninterventional Observational Study Using High-Dose Controlled-Release Oxycodone (CR Oxycodone) for Cancer Pain Management in Outpatient Clinics

Pain Medicine ◽  
2013 ◽  
Vol 14 (12) ◽  
pp. 1866-1872 ◽  
Author(s):  
Sun Kyung Baek ◽  
Hye Won Shin ◽  
Young Jin Choi ◽  
Dae Young Zang ◽  
Do-Yeun Cho ◽  
...  
Keyword(s):  
Pain Management ◽  
Controlled Release ◽  
Observational Study ◽  
Cancer Pain ◽  
Outpatient Clinics ◽  
High Dose ◽  
Cancer Pain Management

Guidelines for use of controlled-release oral morphine in cancer pain management Correlation with clinical experience

1989 ◽  
Vol 12 (4) ◽  
pp. 202???208 ◽  
Author(s):  
Jeanne Lapin ◽  
Russell K. Portenoy ◽  
Nessa Coyle ◽  
Raymond W. Houde ◽  
Kathleen M. Foley
Keyword(s):  
Pain Management ◽  
Controlled Release ◽  
Cancer Pain ◽  
Clinical Experience ◽  
Oral Morphine ◽  
Cancer Pain Management

High-dose oral morphine in cancer pain management: A report of twelve cases

1996 ◽  
Vol 8 (2) ◽  
pp. 144-150 ◽  
Author(s):  
Lukas Radbruch ◽  
Stefan Grond ◽  
Detlev J. Zech ◽  
Albrecht Bischoff
Keyword(s):  
Pain Management ◽  
Cancer Pain ◽  
Oral Morphine ◽  
High Dose ◽  
Cancer Pain Management ◽  
Dose Oral

scholarly journals Cancer pain management with a controlled-release oral morphine preparation

1989 ◽  
Vol 4 (3) ◽  
pp. 146-151 ◽  
Author(s):  
Jeanne Lapin ◽  
Raymond W. Houde ◽  
Robert F. Kaiko ◽  
Nessa Coyle ◽  
Ada Rogers ◽  
...  
Keyword(s):  
Pain Management ◽  
Controlled Release ◽  
Cancer Pain ◽  
Oral Morphine ◽  
Cancer Pain Management

Use of a new novel infusion system for the intrathecal delivery of morphine sulfate in refractory cancer pain management

1998 ◽  
Vol 89 (Supplement) ◽  
pp. 1082A ◽  
Author(s):  
Richard Rauck ◽  
Joan Southern ◽  
Kevin Speight ◽  
Francisco Naveira
Keyword(s):  
Pain Management ◽  
Cancer Pain ◽  
Morphine Sulfate ◽  
Cancer Pain Management ◽  
New Novel ◽  
Infusion System

Oral Ketamine and Transdermal Nitroglycerin as Analgesic Adjuvants to Oral Morphine Therapy for Cancer Pain Management

1999 ◽  
Vol 90 (6) ◽  
pp. 1528-1533. ◽  
Author(s):  
Gabriela R. Lauretti ◽  
Izabel C. P. R. Lima ◽  
Marlene P. Reis ◽  
Wiliam A. Prado ◽  
Newton L. Pereira
Keyword(s):  
Nitric Oxide ◽  
Pain Management ◽  
Cancer Pain ◽  
Visual Analog Scale ◽  
Oral Morphine ◽  
Visual Analog Scale Score ◽  
Test Drug ◽  
Cancer Pain Management ◽  
Analog Scale ◽  
Oral Ketamine

Background Guidelines for cancer pain management include nonsteroidal antiinflammatory drugs with opioids administered in a time-contingent manner. This study was designed to evaluate the role of oral ketamine or transdermal nitroglycerin polymer, a nitric oxide donor, as coadjuvants to oral morphine in cancer pain therapy. Methods After institutional approval and informed patient consent were obtained, 60 patients with cancer pain were randomized to one of four groups (n = 15) and studied prospectively to evaluate analgesia and any adverse effects. A visual analog scale that consisted of a 10-cm line with 0 representing "no pain at all" and 10 representing "the worst possible pain" was introduced. All patients were regularly taking oral amitriptyline 50 mg at bedtime. The morphine regimen was adjusted individually to a maximal oral dose of 80-90 mg/day to keep the visual analog scale score less than 4. When patients reported pain (visual analog scale of 4 or more), despite taking 80-90 mg oral morphine daily, the test drug was added as follows: the control group (CG) received an additional 20 mg oral morphine (10 mg at 12-h intervals); the nitroglycerin group (NG) received a 5-mg nitroglycerin patch daily; the ketamine group (KG) received 0.5 mg/kg oral ketamine at 12-h intervals; and the dipyrone group (DG) received 500 mg oral dipyrone at 6-h intervals. Patients were free to manipulate their daily morphine consumption when the test drug was introduced to keep their visual analog scale score less than 4. Results The groups were similar with respect to demographic data and visual analog scale pain scores before treatment. The visual analog scale scores after the test drug was introduced were similar among the groups. The daily consumption of oral morphine was as follows: on day 15: CG = DG = NG (P > 0.05), CG > KG (P = 0.036); on day 20: CG > NG = KG (P < 0.02) (CG > KG, P < 0.005; CG > NG, P < 0.02), DG > KG (P < 0.05); on day 30: CG = DG > KG = NG (P < 0.05). Patients in the CG and DG groups reported somnolence, but patients in the NG and KG groups did not. Conclusions Low-dose ketamine and transdermal nitroglycerin were effective coadjuvant analgesics. In conjunction with their opioid tolerance-sparing function, joint delivery of ketamine or nitric oxide donors with opiates may be of significant benefit in cancer pain management.

Sign in / Sign up

Export Citation Format

Share Document